...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>International Journal of Molecular Sciences >Engaging Cytotoxic T and NK Cells for Immunotherapy in Chronic Lymphocytic Leukemia
【24h】

Engaging Cytotoxic T and NK Cells for Immunotherapy in Chronic Lymphocytic Leukemia

机译：参与细胞毒性T细胞和NK细胞的免疫治疗在慢性淋巴细胞白血病中

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Chronic lymphocytic leukemia (CLL) is characterized by an acquired immune dysfunction. CLL cells affect the phenotype and function of the entire spectrum of innate and adaptive immune cells, including monocytes, T cells, and natural killer (NK) cells, leading to a tumor-supportive environment and reduced immunosurveillance. Novel immunotherapies like immune checkpoint blockade, bi- and tri-specific antibodies, and chimeric antigen receptor (CAR) T cells use the patients’ immune system to induce therapeutic responses. Although these novel immunotherapies showed impressive results in several B cell lymphomas, responses in CLL were often disappointing. The strong immunomodulatory effect of CLL is believed to play a pivotal role in the low response rates to these immunotherapeutic strategies. In this review, we summarize how CLL influences the function of non-malignant lymphocytes, with a special focus on T and NK cells, two important cellular mediators for immunotherapy. Secondly, we provide a short overview of the activity of several immunotherapeutics in CLL, and discuss how novel strategies may overcome the disappointing response rates in CLL.
机译：慢性淋巴细胞性白血病（CLL）的特征在于获得性免疫功能障碍。 CLL细胞会影响包括单核细胞，T细胞和自然杀伤（NK）细胞在内的先天性和适应性免疫细胞的整个频谱的表型和功能，从而导致肿瘤支持环境并降低免疫监视。诸如免疫检查点封锁，双特异性和三特异性抗体以及嵌合抗原受体（CAR）T细胞之类的新型免疫疗法利用患者的免疫系统来诱导治疗反应。尽管这些新颖的免疫疗法在几种B细胞淋巴瘤中显示出令人印象深刻的结果，但CLL中的反应通常令人失望。据信CLL的强免疫调节作用在对这些免疫治疗策略的低应答率中起关键作用。在这篇综述中，我们总结了CLL如何影响非恶性淋巴细胞的功能，特别关注T和NK细胞，这是免疫疗法的两个重要细胞介体。其次，我们简要概述了CLL中几种免疫疗法的活性，并讨论了新策略如何克服CLL中令人失望的反应率。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号